On Friday, Humacyte Inc (NASDAQ: HUMA) was -5.24% drop from the session before settling in for the closing price of $2.67. A 52-week range for HUMA has been $1.15 – $9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 42.43% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 79.88%. With a float of $125.45 million, this company’s outstanding shares have now reached $155.12 million.
In an organization with 220 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Humacyte Inc stocks. The insider ownership of Humacyte Inc is 19.13%, while institutional ownership is 40.22%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.88% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
You can see what Humacyte Inc (HUMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 754.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Let’s dig in a bit further. During the last 5-days, its volume was 4.97 million. That was better than the volume of 3.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 65.21%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 62.44%, which indicates a significant increase from 47.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.40, while its 200-day Moving Average is $3.41. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $2.67. Second resistance stands at $2.82. The third major resistance level sits at $2.93. If the price goes on to break the first support level at $2.41, it is likely to go to the next support level at $2.30. The third support level lies at $2.15 if the price breaches the second support level.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are 155,119K outstanding shares of the company, which has a market capitalization of 392.45 million. As of now, sales total 0 K while income totals -148,700 K. Its latest quarter income was 520 K while its last quarter net income were 39,140 K.
